Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.36 EUR
Change Today +0.0031 / 0.87%
Volume 333.4K
MLM On Other Exchanges
Symbol
Exchange
BrsaItaliana
Frankfurt
As of 11:30 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Via Olgettina, 58

Milan, MI 20132

Italy

Phone: 39 02 212771

Fax: 39 02 21 27 73 25

MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in a Phase III trial in acute leukaemia patients in first or subsequent complete remission and at high risk of relapse, suitable for haploidentical haematopoietic stem cell transplantation. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has agreements with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MLM:IM €0.36 EUR +0.0031

MLM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MLM.
View Industry Companies
 

Industry Analysis

MLM

Industry Average

Valuation MLM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.1x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOLECULAR MEDICINE SPA, please visit www.molmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.